Related Experiment Video
Updated: Sep 12, 2025
08:32
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
10.4K
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis
Alexandr Ceasovschih1,2, Anastasia Balta1, Essam Shams Aldeen1
1Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, Iasi, Romania.
American Journal of Preventive Cardiology
|August 8, 2025
Summary
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer significant cardiovascular benefits beyond glucose control. These agents demonstrate atheroprotective effects and improve vascular function, making them valuable in managing atherosclerotic cardiovascular disease.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel therapeutic class with established cardiovascular benefits.
- Their impact on atherosclerosis and related vascular conditions requires comprehensive synthesis.
Purpose of the Study:
- To review clinical and preclinical evidence on SGLT2i effects on atherosclerosis, arterial stiffness, and associated cardiovascular diseases.
- To elucidate the mechanisms underlying the atheroprotective advantages of SGLT2i.
Main Methods:
- Systematic review of clinical and preclinical studies.
- Synthesis of evidence on SGLT2i impact on dyslipidemia, coronary artery disease, peripheral artery disease, and stroke.
Main Results:
- SGLT2i demonstrate atheroprotective effects through multiple mechanisms, including anti-inflammatory, antioxidant, and improved vascular function.
- Benefits extend to glycemic control, weight reduction, blood pressure management, and antifibrotic actions.
- SGLT2i exhibit a favorable safety profile and compatibility with combination therapies.
Conclusions:
- SGLT2i offer broad cardiovascular benefits, significantly impacting atherosclerotic cardiovascular disease management.
- These agents are advancing the paradigm of cardiovascular disease care with a favorable safety profile.
- Accumulating evidence supports SGLT2i as key agents in combating atherosclerosis.
Keywords:
Arterial stiffnessAtherosclerosisCardiovascular diseasesCerebrovascular diseaseDyslipidemiaSGLT2 inhibitorsMore Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
262
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
262
01:27Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
01:32Secondary Active Transport
7.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K
01:17Oral Hypoglycemic Agents: Sulfonylureas
332
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
332